• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将埃博拉预测评分工具和快速诊断测试纳入筛查算法的成本效益:决策分析模型。

Cost-effectiveness of incorporating Ebola prediction score tools and rapid diagnostic tests into a screening algorithm: A decision analytic model.

机构信息

Department of Public Health, University of Kisangani, Kisangani, Democratic Republic of Congo (DRC).

National Institute for Biomedical Research, Kinshasa, DRC.

出版信息

PLoS One. 2023 Oct 17;18(10):e0293077. doi: 10.1371/journal.pone.0293077. eCollection 2023.

DOI:10.1371/journal.pone.0293077
PMID:37847703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10581462/
Abstract

BACKGROUND

No distinctive clinical signs of Ebola virus disease (EVD) have prompted the development of rapid screening tools or called for a new approach to screening suspected Ebola cases. New screening approaches require evidence of clinical benefit and economic efficiency. As of now, no evidence or defined algorithm exists.

OBJECTIVE

To evaluate, from a healthcare perspective, the efficiency of incorporating Ebola prediction scores and rapid diagnostic tests into the EVD screening algorithm during an outbreak.

METHODS

We collected data on rapid diagnostic tests (RDTs) and prediction scores' accuracy measurements, e.g., sensitivity and specificity, and the cost of case management and RDT screening in EVD suspect cases. The overall cost of healthcare services (PPE, procedure time, and standard-of-care (SOC) costs) per suspected patient and diagnostic confirmation of EVD were calculated. We also collected the EVD prevalence among suspects from the literature. We created an analytical decision model to assess the efficiency of eight screening strategies: 1) Screening suspect cases with the WHO case definition for Ebola suspects, 2) Screening suspect cases with the ECPS at -3 points of cut-off, 3) Screening suspect cases with the ECPS as a joint test, 4) Screening suspect cases with the ECPS as a conditional test, 5) Screening suspect cases with the WHO case definition, then QuickNavi™-Ebola RDT, 6) Screening suspect cases with the ECPS at -3 points of cut-off and QuickNavi™-Ebola RDT, 7) Screening suspect cases with the ECPS as a conditional test and QuickNavi™-Ebola RDT, and 8) Screening suspect cases with the ECPS as a joint test and QuickNavi™-Ebola RDT. We performed a cost-effectiveness analysis to identify an algorithm that minimizes the cost per patient correctly classified. We performed a one-way and probabilistic sensitivity analysis to test the robustness of our findings.

RESULTS

Our analysis found dual ECPS as a conditional test with the QuickNavi™-Ebola RDT algorithm to be the most cost-effective screening algorithm for EVD, with an effectiveness of 0.86. The cost-effectiveness ratio was 106.7 USD per patient correctly classified. The following algorithms, the ECPS as a conditional test with an effectiveness of 0.80 and an efficiency of 111.5 USD per patient correctly classified and the ECPS as a joint test with the QuickNavi™-Ebola RDT algorithm with an effectiveness of 0.81 and a cost-effectiveness ratio of 131.5 USD per patient correctly classified. These findings were sensitive to variations in the prevalence of EVD in suspected population and the sensitivity of the QuickNavi™-Ebola RDT.

CONCLUSIONS

Findings from this study showed that prediction scores and RDT could improve Ebola screening. The use of the ECPS as a conditional test algorithm and the dual ECPS as a conditional test and then the QuickNavi™-Ebola RDT algorithm are the best screening choices because they are more efficient and lower the number of confirmation tests and overall care costs during an EBOV epidemic.

摘要

背景

埃博拉病毒病(EVD)没有明显的临床特征,这促使人们开发快速筛查工具或寻求新的方法来筛查疑似埃博拉病例。新的筛查方法需要有临床获益和经济效率的证据。到目前为止,还没有证据或确定的算法存在。

目的

从医疗保健的角度评估在疫情爆发期间将埃博拉预测评分和快速诊断检测纳入 EVD 筛查算法的效率。

方法

我们收集了有关快速诊断检测(RDT)和预测评分准确性测量的信息,例如灵敏度和特异性,以及对疑似病例进行病例管理和 RDT 筛查的成本。计算了每位疑似患者的医疗保健服务总成本(个人防护设备、程序时间和标准护理(SOC)成本)和 EVD 的确诊情况。我们还从文献中收集了疑似患者中的 EVD 患病率。我们创建了一个分析决策模型来评估八种筛查策略的效率:1)使用世界卫生组织(WHO)的 Ebola 疑似病例定义筛查疑似病例,2)使用 ECPS 在 -3 分的截止值筛查疑似病例,3)使用 ECPS 作为联合检测筛查疑似病例,4)使用 ECPS 作为条件检测筛查疑似病例,5)使用世界卫生组织(WHO)的 Ebola 疑似病例定义,然后使用 QuickNavi™-Ebola RDT 筛查疑似病例,6)使用 ECPS 在 -3 分的截止值和 QuickNavi™-Ebola RDT 筛查疑似病例,7)使用 ECPS 作为条件检测和 QuickNavi™-Ebola RDT 筛查疑似病例,以及 8)使用 ECPS 作为联合检测和 QuickNavi™-Ebola RDT 筛查疑似病例。我们进行了成本效益分析,以确定一种能使每位正确分类的患者的成本最小化的算法。我们进行了单因素和概率敏感性分析,以测试我们发现的稳健性。

结果

我们的分析发现,双重 ECPS 作为条件检测与 QuickNavi™-Ebola RDT 算法是 EVD 最具成本效益的筛查算法,有效性为 0.86。成本效益比为每例正确分类的患者 106.7 美元。以下算法的成本效益比也较低,包括 ECPS 作为条件检测的有效性为 0.80,效率为 111.5 美元/例,以及 ECPS 作为联合检测与 QuickNavi™-Ebola RDT 算法的有效性为 0.81,成本效益比为每例正确分类的患者 131.5 美元。这些发现对疑似人群中 EVD 的流行率和 QuickNavi™-Ebola RDT 的灵敏度的变化敏感。

结论

本研究结果表明,预测评分和 RDT 可以提高埃博拉病毒的筛查效果。使用 ECPS 作为条件检测算法和双重 ECPS 作为条件检测,然后是 QuickNavi™-Ebola RDT 算法是最佳的筛查选择,因为它们效率更高,并且可以减少确认检测的数量和整个疫情期间的护理成本。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/f384825ca506/pone.0293077.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/a5c08277e99a/pone.0293077.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e386735fc9f6/pone.0293077.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/5f0971a9167b/pone.0293077.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e788399c23a9/pone.0293077.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e737c6cf1e0a/pone.0293077.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/df24c89b77d9/pone.0293077.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/27ecc5c90ce7/pone.0293077.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/f384825ca506/pone.0293077.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/a5c08277e99a/pone.0293077.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e386735fc9f6/pone.0293077.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/5f0971a9167b/pone.0293077.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e788399c23a9/pone.0293077.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/e737c6cf1e0a/pone.0293077.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/df24c89b77d9/pone.0293077.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/27ecc5c90ce7/pone.0293077.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/361f/10581462/f384825ca506/pone.0293077.g008.jpg

相似文献

1
Cost-effectiveness of incorporating Ebola prediction score tools and rapid diagnostic tests into a screening algorithm: A decision analytic model.将埃博拉预测评分工具和快速诊断测试纳入筛查算法的成本效益:决策分析模型。
PLoS One. 2023 Oct 17;18(10):e0293077. doi: 10.1371/journal.pone.0293077. eCollection 2023.
2
Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak.埃博拉病毒病预测评分的制定:疫情期间分诊点埃博拉疑似患者的筛查工具。
PLoS One. 2022 Dec 16;17(12):e0278678. doi: 10.1371/journal.pone.0278678. eCollection 2022.
3
Head-to-head comparison of diagnostic accuracy of four Ebola virus disease rapid diagnostic tests versus GeneXpert® in eastern Democratic Republic of the Congo outbreaks: a prospective observational study.在刚果民主共和国东部疫情中,比较四种埃博拉病毒病快速诊断检测与 GeneXpert® 的诊断准确性:一项前瞻性观察研究。
EBioMedicine. 2023 May;91:104568. doi: 10.1016/j.ebiom.2023.104568. Epub 2023 Apr 19.
4
The diagnostic accuracy of rapid diagnostic tests for Ebola virus disease: a systematic review.埃博拉病毒病快速诊断检测的诊断准确性:系统评价。
Clin Microbiol Infect. 2023 Feb;29(2):171-181. doi: 10.1016/j.cmi.2022.09.014. Epub 2022 Sep 23.
5
Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015.2015 年 1 月至 2 月,在塞拉利昂西部地区的埃博拉留观单位,评估即时护理点血液检测用于埃博拉病毒病的诊断。
Euro Surveill. 2015 Mar 26;20(12):21073. doi: 10.2807/1560-7917.es2015.20.12.21073.
6
Identifying Paucisymptomatic or Asymptomatic and Unrecognized Ebola Virus Disease Among Close Contacts Based on Exposure Risk Assessments and Screening Algorithms.基于暴露风险评估和筛查算法,识别密切接触者中的症状轻微或无症状且未被识别的埃博拉病毒病。
J Infect Dis. 2023 Apr 12;227(7):878-887. doi: 10.1093/infdis/jiac359.
7
Development and Clinical Evaluation of a Rapid Point of Care Test for Ebola Virus Infection in Humans.人类埃博拉病毒感染即时护理点检测的开发和临床评估。
Viruses. 2023 Jan 25;15(2):336. doi: 10.3390/v15020336.
8
Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.使用埃博拉病毒疫苗接种在中低收入国家的动态过渡建模进行经济评估。
J Med Econ. 2021 Nov;24(sup1):1-13. doi: 10.1080/13696998.2021.2002092.
9
Cost-effectiveness analysis of malaria rapid diagnostic test in the elimination setting.消除疟疾背景下疟疾快速诊断检测的成本效益分析。
Infect Dis Poverty. 2020 Sep 29;9(1):135. doi: 10.1186/s40249-020-00745-9.
10
Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT.尼日利亚疟疾快速诊断检测、显微镜检查和症状处理方法的成本效益分析:对 ACT 广泛应用部署的影响。
Malar J. 2009 Nov 23;8:265. doi: 10.1186/1475-2875-8-265.

引用本文的文献

1
Dynamic modeling of mortality risk factors in Ebola virus disease using logistic regression on unbalanced panel data from a randomized controlled trial in the Democratic Republic of Congo.利用刚果民主共和国一项随机对照试验的不平衡面板数据进行逻辑回归,对埃博拉病毒病死亡风险因素进行动态建模。
PLOS Glob Public Health. 2025 Jul 11;5(7):e0004901. doi: 10.1371/journal.pgph.0004901. eCollection 2025.

本文引用的文献

1
Development of Ebola virus disease prediction scores: Screening tools for Ebola suspects at the triage-point during an outbreak.埃博拉病毒病预测评分的制定:疫情期间分诊点埃博拉疑似患者的筛查工具。
PLoS One. 2022 Dec 16;17(12):e0278678. doi: 10.1371/journal.pone.0278678. eCollection 2022.
2
Risk Prediction Score for Pediatric Patients with Suspected Ebola Virus Disease.疑似埃博拉病毒病患儿的风险预测评分。
Emerg Infect Dis. 2022 Jun;28(6):1189-1197. doi: 10.3201/eid2806.212265.
3
Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study.
2018-2019 年刚果民主共和国东部暴发期间使用的三种埃博拉快速诊断检测试剂的现场性能:一项回顾性、多中心观察性研究。
Lancet Infect Dis. 2022 Jun;22(6):891-900. doi: 10.1016/S1473-3099(21)00675-7. Epub 2022 Mar 14.
4
Evaluation of Early Warning, Alert and Response System for Ebola Virus Disease, Democratic Republic of the Congo, 2018-2020.2018-2020 年刚果民主共和国埃博拉病毒病早期预警、警报和应对系统评估。
Emerg Infect Dis. 2021 Dec;27(12):2988-2998. doi: 10.3201/eid2712.210290.
5
Micro-costing in health and medicine: a critical appraisal.卫生与医学领域的微观成本核算:批判性评估
Health Econ Rev. 2021 Jan 6;11(1):1. doi: 10.1186/s13561-020-00298-5.
6
Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis.世界卫生组织埃博拉病例定义的临床和流行病学表现:系统评价和荟萃分析。
Lancet Infect Dis. 2020 Nov;20(11):1324-1338. doi: 10.1016/S1473-3099(20)30193-6. Epub 2020 Jun 25.
7
Ebola Virus Disease Outbreak - Democratic Republic of the Congo, August 2018-November 2019.2018 年 8 月至 2019 年 11 月刚果民主共和国埃博拉病毒病疫情。
MMWR Morb Mortal Wkly Rep. 2019 Dec 20;68(50):1162-1165. doi: 10.15585/mmwr.mm6850a3.
8
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
9
Enhancing laboratory capacity during Ebola virus disease (EVD) heightened surveillance in Liberia: lessons learned and recommendations.在利比里亚埃博拉病毒病(EVD)期间加强实验室能力以强化监测:经验教训与建议
Pan Afr Med J. 2019 May 29;33(Suppl 2):8. doi: 10.11604/pamj.supp.2019.33.2.17366. eCollection 2019.
10
Clinical Evaluation of QuickNavi-Ebola in the 2018 Outbreak of Ebola Virus Disease in the Democratic Republic of the Congo.《QuickNavi-Ebola 在 2018 年刚果民主共和国埃博拉疫情中的临床评估》。
Viruses. 2019 Jun 28;11(7):589. doi: 10.3390/v11070589.